Aptevo Provides 3Q26 Business Update Highlighting Growing Momentum for Mipletamig and Reports Third Quarter Financial Results
Key Highlights
- ➤Mipletamig triplet produced 79% CR/CRi in evaluable TP53-mutated AML patients
- ➤Ten of 47 frontline patients advanced to potentially curative stem cell transplantation
- ➤RAINIER Phase 1b dose optimization targeted for completion by year-end 2026
- ➤Aptevo secured approximately $4.5 million gross financing in August
- ➤Third-quarter net loss narrowed to $6.5 million from $7.5 million year-over-year
Expert Statements
Jeff Lamothe, President and Chief Executive Officer of Aptevo Therapeutics
“We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline”
Jeff Lamothe, President and Chief Executive Officer of Aptevo Therapeutics
“We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability.”
Jeff Lamothe, President and Chief Executive Officer of Aptevo Therapeutics
“Each of these findings adds a new dimension to the mipletamig story and strengthens our conviction in its potential to become an important addition to frontline AML treatment.”
Jeff Lamothe, President and Chief Executive Officer of Aptevo Therapeutics
“At the same time, we are advancing a new generation of cancer therapies designed to bring the power of our multispecific technology to more patients and more types of cancer.”
Jeff Lamothe, President and Chief Executive Officer of Aptevo Therapeutics
“As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders.”
SEATTLE, WA / ACCESS Newswire / November 16, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today reported financial results for the quarter ended September 30, 2026, and highlighted new clinical findings supporting mipletamig's potential in frontline acute myeloid leukemia (AML), progress in optimizing treatment tolerability, and continued advancement of its next-generation cancer treatment pipeline.
"We are entering an exciting period for Aptevo, with growing clinical evidence that reinforces our confidence in mipletamig and meaningful progress across our broader pipeline," said Jeff Lamothe, President and Chief Executive Officer of Aptevo. "We are seeing strong clinical activity in patients with some of the most difficult-to-treat forms of AML, patients advancing to potentially curative stem cell transplantation, and important improvements in tolerability. Each of these findings adds a new dimension to the mipletamig story and strengthens our conviction in its potential to become an important addition to frontline AML treatment. At the same time, we are advancing a new generation of cancer therapies designed to bring the power of our multispecific technology to more patients and more types of cancer. As we approach important clinical and development milestones, we believe Aptevo is increasingly well positioned to translate the strength of our science into meaningful opportunities for patients and long-term value for shareholders."
Get started
Create a free account to read the full story.
